Incyte (INCY) Free Cash Flow (2010 - 2026)
Incyte's (INCY) quarterly Free Cash Flow came in at $495.2 million in Q2 2026, up 1829.52% YoY from $25.7 million in Q2 2025, and up 37.89% on a QoQ basis from $359.2 million in Q1 2026.
Analysis
Incyte (INCY) Free Cash Flow (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Free Cash Flow data on file, last reported at $495.2 million in Q2 2026.
- Quarterly Free Cash Flow rose 1829.52% year-over-year to $495.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 billion (up 100.45% YoY) and the FY2025 annual result came in at $1.4 billion, up 443.87% from the prior year.
- Free Cash Flow grew to $495.2 million in Q2 2026, from $359.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $544.6 million in Q3 2025 to a low of -$629.7 million in Q2 2024.
- A 5-year average of $211.9 million and a median of $262.6 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow sank 310.47% — and 2026, when it surged 1829.52%.
- Tracing INCY's Free Cash Flow over 5 years: stood at $262.4 million in 2022, then slumped by 44.56% to $145.5 million in 2023, then soared by 150.12% to $363.8 million in 2024, then surged by 43.31% to $521.4 million in 2025, then retreated by 5.02% to $495.2 million in 2026.
- The last three Free Cash Flow figures came in at $495.2 million (Q2 2026), $359.2 million (Q1 2026), and $521.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 495.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 495.25 Mn |
| Mar 31, 2026 | 359.15 Mn |
| Dec 31, 2025 | 521.42 Mn |
| Sep 30, 2025 | 544.64 Mn |
| Jun 30, 2025 | 25.67 Mn |
| Mar 31, 2025 | 262.90 Mn |
| Dec 31, 2024 | 363.83 Mn |
| Sep 30, 2024 | 305.68 Mn |
| Jun 30, 2024 | -629.71 Mn |
| Mar 31, 2024 | 209.26 Mn |
| Dec 31, 2023 | 145.46 Mn |
| Sep 30, 2023 | 136.86 Mn |
| Jun 30, 2023 | 299.19 Mn |
| Mar 31, 2023 | -117.51 Mn |
| Dec 31, 2022 | 262.39 Mn |
| Sep 30, 2022 | 268.57 Mn |
| Jun 30, 2022 | 162.41 Mn |
| Mar 31, 2022 | 198.74 Mn |
| Dec 31, 2021 | 80.89 Mn |
| Sep 30, 2021 | 222.95 Mn |